FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583616640> ?p ?o ?g. }

• W2583616640 endingPage "3621" @default.
• W2583616640 startingPage "3621" @default.
• W2583616640 abstract "Abstract Abstract 3621 Introduction: The mechanism of MDR (multiple drug resistance) in acute myelogenous leukemia (AML) is complicated. Activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway plays a crucial role in cellular proliferation, survival and apoptosis in leukemia cells. Both histone deacetylase (HDAC) inhibitor and proteasome inhibitor have emerged as new kinds of therapeutic drugs against multiple myeloma (MM), their anti-tumor effects are later confirmed in other hematologic malignancies. Panobinostat, a novel HDAC inhibitor, can improve histone acetylation level and non-histone acetylase level associated with cell growth and apoptosis. Anticancer and drug-sensitization effect of Bortezomib have been investigated in lymphoma and leukemia through inhibiting NF-κB pathway. In this study, we evaluate the synergistic effect of panobinostat and bortezomib on proliferation, apoptosis and drug resistance in chemoresistant AML cells and its molecular mechanism. Methods: HL60/ADR cell with high expression of MRP1 was maintained with adriamycin to ensure its drug resistance, which displayed almost 80-fold more resistance to adriamycin than the parental line. Bone marrow samples were obtain from five patients with refractory AML except M3. The synergistic effect of Panobinostat and Bortezomib in HL60/ADR cells and refractory acute myelogenous leukemia (AML) primary cells was determined by isobologram analysis based on cell viability in MTT assay. Apoptosis assessment and analysis of sensitivity to adriamycin were analyzed by fluorescence-activated cell sorting (FACS) and MTT. The change in protein level of HL60/ADR cell was analyzed by western blotting to further study its molecular mechanism. Results: Synergistic cytotoxicity was observed in the combined treatment with Panobinostat and Bortezomib in HL-60/ADM cells and primary patients AML cells. More powerful synergy was observed in 21nmol/L Panobinostat in combination with 12nmol/L Bortezomi, which CI value equal to 0.531 and 0.498. The accumulation of adriamycin in HL60/ADM cells was significantly increased by the combination (64.81±3.69%) compared with treatment with Panobinostat or Bortezomib alone (28.96±2.52% or 37.29±3.71%) (P <0.05). Simultaneously, MRP1 expression was down regulated in the combination (57.78±3.34%) (P <0.05), which was accompany with susceptibility to adriamycin. The synergistic cytotoxicity was partially depended on downregulation of X-linked inhibitor of apoptosis protein (XIAP), as well as the extrinsic apoptosis pathway consistent with initiator caspase-8 activation and downstream cleavage of caspase-3 and PARP. Our findings indicated that the combined treatment significantly induced apoptosis and intercellular adriamycin accumulation via p53-dependent Bcl-2 and MRP1 downregulation in HL60/ADR cells. Moreover, Panobinostat and Bortezomib individually attenuated phosphorylated form of AKT, which was further abrogated by the combination. The phosphorylation-dependent state of IKKα was significantly decreased by the combined treatment, and blockade of NF-κB nuclear translocation was more obvious in the cooperation of IKKα inactivation and proteasome inhibition. Conclusion: Our results indicate that combination of Panobinostat and Bortezomib exerted a synergistic cytotoxicity in chemoresistant AML cells, and sensitivity to adriamycin was also increased in HL60/ADR cells. Cooperation of multiple apoptotic molecules and intracellular drug accumulation contributed to the synergistic interaction via inhibition of Akt/NF-κB pathway. These findings provided a rationale for clinic protocols using Panobinostat and Bortezomib to overcome drug resistance and improve therapeutic effect in refractory AML patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W2583616640 created "2017-02-10" @default.
• W2583616640 creator A5034407018 @default.
• W2583616640 creator A5043267366 @default.
• W2583616640 creator A5051764626 @default.
• W2583616640 creator A5055111936 @default.
• W2583616640 creator A5074642572 @default.
• W2583616640 creator A5084303558 @default.
• W2583616640 date "2011-11-18" @default.
• W2583616640 modified "2023-09-29" @default.
• W2583616640 title "Synergistic Effect of Panobinostat and Bortezomib on Chemoresistant Acute Myelogenous Leukemia Cells Via Akt/NF-κB Pathway," @default.
• W2583616640 doi "https://doi.org/10.1182/blood.v118.21.3621.3621" @default.
• W2583616640 hasPublicationYear "2011" @default.
• W2583616640 type Work @default.
• W2583616640 sameAs 2583616640 @default.
• W2583616640 citedByCount "2" @default.
• W2583616640 countsByYear W25836166402012 @default.
• W2583616640 countsByYear W25836166402023 @default.
• W2583616640 crossrefType "journal-article" @default.
• W2583616640 hasAuthorship W2583616640A5034407018 @default.
• W2583616640 hasAuthorship W2583616640A5043267366 @default.
• W2583616640 hasAuthorship W2583616640A5051764626 @default.
• W2583616640 hasAuthorship W2583616640A5055111936 @default.
• W2583616640 hasAuthorship W2583616640A5074642572 @default.
• W2583616640 hasAuthorship W2583616640A5084303558 @default.
• W2583616640 hasConcept C104317684 @default.
• W2583616640 hasConcept C185592680 @default.
• W2583616640 hasConcept C190283241 @default.
• W2583616640 hasConcept C203014093 @default.
• W2583616640 hasConcept C2776364478 @default.
• W2583616640 hasConcept C2777478702 @default.
• W2583616640 hasConcept C2778305200 @default.
• W2583616640 hasConcept C2778367456 @default.
• W2583616640 hasConcept C2778461978 @default.
• W2583616640 hasConcept C2778729363 @default.
• W2583616640 hasConcept C2778903051 @default.
• W2583616640 hasConcept C2780225316 @default.
• W2583616640 hasConcept C2780783641 @default.
• W2583616640 hasConcept C502942594 @default.
• W2583616640 hasConcept C55493867 @default.
• W2583616640 hasConcept C64927066 @default.
• W2583616640 hasConcept C71924100 @default.
• W2583616640 hasConcept C75217442 @default.
• W2583616640 hasConcept C86554907 @default.
• W2583616640 hasConcept C98274493 @default.
• W2583616640 hasConceptScore W2583616640C104317684 @default.
• W2583616640 hasConceptScore W2583616640C185592680 @default.
• W2583616640 hasConceptScore W2583616640C190283241 @default.
• W2583616640 hasConceptScore W2583616640C203014093 @default.
• W2583616640 hasConceptScore W2583616640C2776364478 @default.
• W2583616640 hasConceptScore W2583616640C2777478702 @default.
• W2583616640 hasConceptScore W2583616640C2778305200 @default.
• W2583616640 hasConceptScore W2583616640C2778367456 @default.
• W2583616640 hasConceptScore W2583616640C2778461978 @default.
• W2583616640 hasConceptScore W2583616640C2778729363 @default.
• W2583616640 hasConceptScore W2583616640C2778903051 @default.
• W2583616640 hasConceptScore W2583616640C2780225316 @default.
• W2583616640 hasConceptScore W2583616640C2780783641 @default.
• W2583616640 hasConceptScore W2583616640C502942594 @default.
• W2583616640 hasConceptScore W2583616640C55493867 @default.
• W2583616640 hasConceptScore W2583616640C64927066 @default.
• W2583616640 hasConceptScore W2583616640C71924100 @default.
• W2583616640 hasConceptScore W2583616640C75217442 @default.
• W2583616640 hasConceptScore W2583616640C86554907 @default.
• W2583616640 hasConceptScore W2583616640C98274493 @default.
• W2583616640 hasIssue "21" @default.
• W2583616640 hasLocation W25836166401 @default.
• W2583616640 hasOpenAccess W2583616640 @default.
• W2583616640 hasPrimaryLocation W25836166401 @default.
• W2583616640 hasRelatedWork W1966528856 @default.
• W2583616640 hasRelatedWork W2149340130 @default.
• W2583616640 hasRelatedWork W2383299854 @default.
• W2583616640 hasRelatedWork W2385169010 @default.
• W2583616640 hasRelatedWork W2585926313 @default.
• W2583616640 hasRelatedWork W2738602720 @default.
• W2583616640 hasRelatedWork W2887183852 @default.
• W2583616640 hasRelatedWork W3000746301 @default.
• W2583616640 hasRelatedWork W3010795316 @default.
• W2583616640 hasRelatedWork W4362495438 @default.
• W2583616640 hasVolume "118" @default.
• W2583616640 isParatext "false" @default.
• W2583616640 isRetracted "false" @default.
• W2583616640 magId "2583616640" @default.
• W2583616640 workType "article" @default.